Usage Examples
- The Phase 3 protocol is a hybrid DCT: in-person visits for the pivotal endpoint, eConsent and home-delivered drug for everything else.
- Before we decentralize the safety labs, show me the delegation log for every local phlebotomy provider.
- The DCT design cut participant site visits from twelve to three, but it moved the entire drug accountability burden onto us.
What is Decentralized Clinical Trial (DCT)?
Decentralized Clinical Trials are clinical investigations in which some or all participant activities, including consent, dosing, assessments and safety monitoring, happen at the participant's home or a local provider instead of the investigator's research site.
Decentralized clinical trials exist because the traditional model asks a sick participant to travel repeatedly to a research site, and that geography quietly decides who gets enrolled. Recruitment stalls, dropout rises, and the enrolled population skews toward whoever lives near an academic center. Decentralized designs move the trial to the participant, so that eligibility rather than travel distance determines who takes part.
A decentralized clinical trial covers the activities that can be relocated: remote screening, electronic consent, direct-to-participant shipment of investigational product, home nursing visits, telehealth assessments, local laboratory draws, and wearable data capture. What a decentralized clinical trial does not create is a separate regulatory regime. No DCT-specific rule set exists; the study still runs under 21 CFR Parts 312, 50 and 56.
In practice, a decentralized clinical trial is designed element by element rather than adopted wholesale. Sponsors map every protocol activity, decide which can move off site without degrading the endpoint, then build the controls that follow: delegated tasks logged against qualified local providers, validated systems for remotely captured data, drug accountability that survives shipment to a home address, and safety oversight of participants the investigator never meets in person.
Not to be confused with
- Hybrid trial
- a hybrid trial keeps some mandatory on-site visits and decentralizes the rest. Hybrid is a point on the DCT spectrum, not an alternative to it; only a fully decentralized design removes the site visit entirely.
- Remote monitoring
- remote monitoring is a sponsor oversight activity, reviewing site data without travelling to the site, under 21 CFR 312.56. A DCT relocates the participant's activities, not the monitor's.
- Virtual trial
- "virtual trial" is loose shorthand implying no human contact. Most decentralized trials still involve in-person home nursing, local phlebotomy, and physical shipment of investigational product.
- Real-world evidence study
- an RWE study analyses data generated in routine care, outside a protocol. A decentralized trial is still a prospective interventional study with a protocol, an IRB, and an investigator of record.
A decentralized design changes where obligations are discharged, not which obligations apply.
What you must do
- 1Hold the investigator accountable for protecting the rights, safety, and welfare of subjects under their care, whichever delegated party actually performs the home or telehealth visit21 CFR 312.60
- 2Document informed consent on an IRB-approved written form, signed and dated by the subject or a legally authorized representative, with a copy given to the person signing, including when consent is captured remotely21 CFR 50.27
- 3Maintain records of drug disposition, including dates, quantity, and use by subjects, when investigational product ships directly to a participant's home21 CFR 312.62
- 4Monitor the progress of all clinical investigations conducted under the IND, and either secure compliance or discontinue shipments when a decentralized investigator falls out of compliance21 CFR 312.56
- 5Validate the systems used to capture remote data, including eConsent, ePRO and wearables, for accuracy, reliability, consistent intended performance, and the ability to discern invalid or altered records21 CFR 11.10
Common mistakes
Treating "decentralized" as its own regulatory category
there is no DCT part of the CFR. Teams search for DCT-specific requirements, find none, and proceed as though the design is lightly regulated. Inspectors cite the ordinary parts, 312, 50 and 56, and the findings land on the investigator of record.
Delegating home visits without documenting the delegation
a local nurse or telehealth clinician performing a protocol activity is performing an investigator-delegated task. Without the task log, training record and qualification evidence, the data exists but the record supporting it does not, and the visit is unusable on inspection.
Shipping investigational product to homes with only courier tracking
21 CFR 312.62 requires records of drug disposition, including dates, quantity, and use by subjects. A delivery confirmation is not accountability; without receipt, storage-condition and return records for every participant, batch reconciliation will not close at study end.
When This Matters
- The Phase 3 protocol is a hybrid DCT: in-person visits for the pivotal endpoint, eConsent and home-delivered drug for everything else.
- Before we decentralize the safety labs, show me the delegation log for every local phlebotomy provider.
- The DCT design cut participant site visits from twelve to three, but it moved the entire drug accountability burden onto us.
Frequently Asked Questions
No. Most decentralized clinical trials are hybrid, mixing remote activities with in-person site visits for endpoints that need direct measurement. Full decentralization is possible, but the design has to show that every safety assessment and pivotal endpoint can be captured reliably without the participant attending a site.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Clinical Workflows
Track clinical trial regulations across global markets
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
